Expanded Access Policy
At iECURE, we are focused on transforming the lives of patients suffering from devastating liver disorders utilizing new advancements in genetic medicine.
We are dedicated to working with families, physicians, advocacy groups, researchers, and health authorities worldwide to assess the safety and effectiveness of a treatment in a way that is meaningful to the patient.
We conduct clinical trials to evaluate our investigational products and gain an understanding of the safety and efficacy of the therapy in a specific population, which could support regulatory approval of the treatment. We are committed to making all approved therapies widely available as rapidly as possible.
Expanded access, also known as compassionate use, is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
We do not offer expanded access for our investigational products. We believe that it is through clinical trials and regulatory approval that we can ultimately ensure safe and timely access to our medicines for as many patients as possible suffering from these devastating diseases. Once we have published results from a clinical trial that suggest a therapy may provide benefit for patients with acceptable safety, we will consider options such as expanded access.
Treating physicians, patients, and caregivers can learn more about our investigational products in ongoing clinical trials by visiting www.clinicaltrials.gov. If you have additional questions, please speak with your physician, or contact email@example.com. Please do not send any personal or private health information to this email address.